More evidence supports BP-lowering in type 2 diabetes
ADVANCE trial data suggests antihypertensives beneficial across a range of baseline characteristics
Intensified BP-lowering therapy cuts mortality and major vascular events in patients with type 2 diabetes, regardless of their baseline blood pressure or CVD risk, trial results show.
In the ADVANCE trial, more than 11,000 people with type 2 diabetes and at least one CVD risk factor were randomised to either intensive antihypertensive therapy with fixed combinations of perindopril-indapamide (4mg/1.25mg) or placebo.
